183 related articles for article (PubMed ID: 34128936)
1. [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.].
Danesi R; Cremolini C; Ciccarone F; Lorusso D
Recenti Prog Med; 2021 Jun; 112(6):444-453. PubMed ID: 34128936
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
4. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
5. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
[TBL] [Abstract][Full Text] [Related]
8. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
9. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS; Jacobs IA; Burkes RL
Target Oncol; 2017 Oct; 12(5):599-610. PubMed ID: 28801849
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
12. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
13. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
14. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Buske C; Ogura M; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
[TBL] [Abstract][Full Text] [Related]
15. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
16. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders.
Mirjalili SZ; Sabourian R; Sadeghalvad M; Rezaei N
Int Immunopharmacol; 2021 Dec; 101(Pt B):108305. PubMed ID: 34741996
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: what the oncologist should know.
Thill M; Thatcher N; Hanes V; Lyman GH
Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
[TBL] [Abstract][Full Text] [Related]
19. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
20. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
